NCT Number: NCT00116675
Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects
The primary purpose of this study is to evaluate the effectiveness in pediatric subjects of three different strengths of resiquimod gel applied to common wart(s) three times a week for four weeks.
A second purpose is to evaluate the safety of the drug.
Looking for future studies?
Notify MeKey information
Conditions
Age range
3 year–11 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Primary location
Children's Clinic of Jonesboro, PA, Jonesboro, Arkansas, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Diagnosis of common warts
- Ages between 3 to 11
Exclusion criteria
- Other types of wart(s), ie. plantar
- Currently participating in another clinical study
- Chronic viral hepatitis B or C
Treatment and study plan
Primary outcomes
-
Clearance of treated wart(s)
Secondary outcomes
-
Partial clearance of treated wart(s)
-
Wart recurrence
Sponsors and collaborators
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Registry information
Official study title
A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for 4 Weeks for the Treatment of Common Warts in Pediatric Subjects
Important dates
- Study start
- 2005
- Study completion
- 2006
- First posted
- Jul 1, 2005
- Registry last updated
- Feb 19, 2007
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome
NCT02231879
Agammaglobulinemia, Agranulocytosis
Bethesda, Maryland, United States
View Trial DetailsCombination Therapy for Warts: Candida Antigen vs. Topical Keratolytic
NCT07329907
DNA Virus Infections, Human Papilloma Virus (HPV)
Banhā, Qalyubia Governorate, Egypt
View Trial DetailsIntralesional HPV Vaccine for Condylomata
NCT05087849
Communicable Diseases, Condyloma
San Francisco, California, United States
View Trial DetailsSafety and Efficacy of VDMN-21 Patch in Subjects With Common Warts
NCT05799157
Common Wart, DNA Virus Infections
Fort Smith, Arkansas, United States
View Trial Details